The global market for Osteoporosis
Therapeutics is projected to reach US$13.3 billion by 2025, driven by rising
awareness over the growing problem of osteoporosis and the ensuing emphasis on
early diagnosis and treatment. With the percentage share of people aged 60 plus
in the global population mix forecast to reach 21.5% from the current 12.7%,
burden of osteoporosis will increase significantly accounting for over 75% of
all fractures among the elderly. Although largely preventable, fractures result
in long-term injuries, severe pain, long-term disability and high mortality. In
the Europe, India, Japan and the United States over 150 million people live with
osteoporosis, a number poised to rise significantly in the coming years. Medical
emphasis on prevention and early diagnosis will therefore gain prominence
providing the cornerstone for growth in the market. As losses in bone mineral
density (BMD) is high in the elderly, aging population remains a key growth
catalyst, with the risk of osteoporotic hip, vertebral and wrist fracture
tripling with age. Economic burden of osteoporotic fractures (OFs) will grow bigger
in sync with the aging population growth from 729.3 million people in the age
group 65+ in 2020 to over 852.5 million by 2025. The cost of long-term
disability from osteoporosis is huge since over 25% of elderly suffering from hip
fracture will require permanent nursing home care.
Also driving prevalence rates are
factors such as rising incidence of vitamin D deficiencies, anorexia nervosa,
growing cancer epidemic and increase in the number of patients undergoing
chemotherapy and/or using glucocorticoids both of which tend to accelerate the
loss of bone mineral density. The
scenario offers a robust outlook for osteoporosis
therapeutics. Read More…
Comments
Post a Comment